Show simple item record

dc.contributor.authorErel, C. Tamer
dc.contributor.authorKaleli, Semih
dc.contributor.authorSenturk, Levent M.
dc.date.accessioned2021-03-05T19:41:14Z
dc.date.available2021-03-05T19:41:14Z
dc.date.issued2006
dc.identifier.citationErel C. T. , Senturk L. M. , Kaleli S., "Tibolone and breast cancer", POSTGRADUATE MEDICAL JOURNAL, cilt.82, ss.658-662, 2006
dc.identifier.issn0032-5473
dc.identifier.otherav_d0677735-6112-401f-9710-6962a6da1c12
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/137789
dc.identifier.urihttps://doi.org/10.1136/pgmj.2005.037184
dc.description.abstractTibolone is a relatively new drug for postmenopausal women, which is structurally related to 19-nortestosterone derivatives and exhibits weak oestrogenic, progestogenic and androgenic activities. The effect of tibolone on breast tissue is still obscure. In vitro studies have shown conflicting results regarding the effects of tibolone on breast cells. On the other hand, although epidemiological studies show an increase in the risk of breast cancer among women treated with tibolone, accumulation of data obtained from radiological studies presents promising results. However, the safety of tibolone with regard to breast tissue needs to be investigated further, especially through well- designed, large-scale, randomised-controlled trials.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectTıp
dc.subjectTemel Tıp Bilimleri
dc.titleTibolone and breast cancer
dc.typeMakale
dc.relation.journalPOSTGRADUATE MEDICAL JOURNAL
dc.contributor.department, ,
dc.identifier.volume82
dc.identifier.issue972
dc.identifier.startpage658
dc.identifier.endpage662
dc.contributor.firstauthorID180045


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record